Evolve Private Wealth LLC Makes New Investment in Natera, Inc. $NTRA

Key Points

• Evolve Private Wealth LLC bought 4,929 Natera shares worth approximately $1.34 million in the second quarter, while institutional investors collectively own 99.90% of the company.
• Natera insiders sold 181,045 shares valued at about $41.3 million over the past 90 days, including substantial sales by directors Herm Rosenman and Gail Boxer Marcus.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and a $319.38 price target. Natera recently reported quarterly revenue of $752.75 million, up 37.7% year over year, and exceeded its expected loss per share.

Evolve Private Wealth LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,929 shares of the medical research company's stock, valued at approximately $1,338,000.

A number of other hedge funds and other institutional investors have also modified their holdings of NTRA. Trust Co. of Vermont acquired a new stake in shares of Natera in the second quarter worth $26,000. Reflection Asset Management bought a new position in Natera during the fourth quarter worth $29,000. Elevation Wealth Partners LLC acquired a new position in Natera during the 2nd quarter valued at $30,000. Palladiem LLC bought a new stake in Natera in the 4th quarter valued at $31,000. Finally, Horizon Investments LLC bought a new stake in Natera in the 3rd quarter valued at $32,000. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In related news, Director Herm Rosenman sold 16,530 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares of the company's stock, valued at $1,062,500. This represents a 79.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director owned 6,183 shares in the company, valued at $1,343,009.43. This represents a 64.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 181,045 shares of company stock worth $41,330,968 over the last 90 days. 5.05% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NTRA shares. TD Cowen lifted their target price on shares of Natera from $325.00 to $340.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Citigroup upped their price target on shares of Natera from $315.00 to $365.00 and gave the stock a "buy" rating in a research report on Thursday, August 13th. BTIG Research increased their price objective on Natera from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Leerink Partners set a $330.00 price target on shares of Natera in a research report on Friday, August 7th. Finally, The Goldman Sachs Group assumed coverage on Natera in a report on Friday, June 5th. They set a "neutral" rating and a $245.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $332.03 on Monday. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56. The company's 50 day moving average price is $274.24 and its two-hundred day moving average price is $229.38. The firm has a market cap of $47.86 billion, a PE ratio of -244.14 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business's quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. On average, research analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source